{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Natural Micronised Progesterone (NMP) including
Oral NMP SR formulation Survey in Luteal Phase Defect (LPD)
  1. What proportion of patients of luteal phase defects causing infertility do you usually see in your clinical practice in a month *

  2. Which of following patient profile is most common for luteal phase support? *

  3. Which route of administration do the patients usually prefer for NMP? *

  4. Oral progesterone formulation is prescribed in how many percentages of patients requiring luteal phase support? *

  5. Vaginal progesterone formulation (Gel/Capsule) is prescribed in how many percentages of patients requiring luteal phase support? *

  6. In your practice, which of the following molecule/s do you prefer most for luteal phase support in infertility? *

  7. In your practice, which formulation of natural Micronised progesterone do you prefer most? *

  8. How will you rate the effectiveness of NMP-SR (Sustained Release) preparation? *

  9. How will you rate the compliance of NMP-SR (Sustained Release) preparation compared to vaginal progesterone preparation? *

  10. With Oral NMP capsule, How many percentage of patients complaint about sedation/dizziness? *

  11. Due to sustained release property, Oral NMP SR minimizes first pass metabolism, How many percentage of patients complaint about sedation/dizziness with oral NMP SR formulation? *

  12. Which strength of oral NMP SR do you prefer most for luteal phase support? *

  13. Which dosage frequency of oral NMP SR do you prefer most for luteal phase support? *

  14. In your practice, when do you usually start treatment of luteal phase support? *

  15. In your practice, till how many weeks of gestation do you usually give treatment with NMP for luteal phase support in infertility? *

  16. How many percentages of patients express resistance to use progesterone by vaginal route or request you to change route? *

  17. Do you counsel the patients given vaginal NMP to switch to oral if unable to take vaginally? *

  18. What is the dose change for vaginal to oral switch of NMP in such patients? *

  19. In your clinical practice, for which of the following reasons do you prefer NMP sutained release preparation? *

  20. How do you rate the immunomodulatory property of NMP for Luteal Phase Support? *

  21. How do you rate the “in-phase” secretory property of NMP for Luteal Phase Support? *

  22. In your practice, do you give NMP for unexplained recurrent pregnancy loss? *

  23. In how many percentages of patients, do you prefer progesterone injection for luteal phase support? *

  24. For parenteral progesterone injection which is your most common preference? *

  25. In how many percentages of patients, do you prefer vaginal progesterone gel for luteal phase support? *

  26. Do you routinely measure progesterone levels in patients on NMP for luteal phase support? *